|
US7625859B1
(en)
*
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
|
US20040001827A1
(en)
*
|
2002-06-28 |
2004-01-01 |
Dennis Mark S. |
Serum albumin binding peptides for tumor targeting
|
|
ES2270893T3
(es)
*
|
1999-12-24 |
2007-04-16 |
Genentech, Inc. |
Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
|
|
US20050287153A1
(en)
*
|
2002-06-28 |
2005-12-29 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
|
US20060228364A1
(en)
*
|
1999-12-24 |
2006-10-12 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
|
PT1282443E
(pt)
*
|
2000-05-19 |
2009-12-04 |
Genentech Inc |
Análise de detecção génica para melhorar a probabilidade de uma resposta eficaz a uma terapia do cancro com um antagonista de erbb
|
|
AU2002355477B2
(en)
*
|
2001-08-03 |
2008-09-25 |
Medical Research Council |
Method of identifying a consensus sequence for intracellular antibodies
|
|
CA2481515C
(en)
*
|
2002-04-10 |
2013-10-01 |
Genentech, Inc. |
Anti-her2 antibody variants
|
|
WO2005080432A2
(en)
|
2004-02-19 |
2005-09-01 |
Genentech, Inc. |
Cdr-repaired antibodies
|
|
KR20110050567A
(ko)
|
2004-07-22 |
2011-05-13 |
제넨테크, 인크. |
Ｈｅｒ２ 항체 조성물
|
|
RU2007116973A
(ru)
*
|
2004-10-05 |
2008-11-20 |
Дженентек, Инк. (Us) |
Терапевтические средства с пониженной токсичностью
|
|
EP1807106A2
(en)
*
|
2004-10-05 |
2007-07-18 |
Oregon Health and Science University |
Compositions and methods for treating disease
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
UA94899C2
(ru)
|
2005-01-21 |
2011-06-25 |
Дженентек, Инк. |
Фиксированное дозирование антител к her
|
|
DK1850874T3
(da)
|
2005-02-23 |
2013-11-11 |
Genentech Inc |
Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
|
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
|
|
PE20070207A1
(es)
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
|
EP1957540B1
(en)
*
|
2005-12-02 |
2012-06-13 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
|
BRPI0715829A2
(pt)
|
2006-08-21 |
2013-07-23 |
Hoffmann La Roche |
terapia de tumor com um anticorpo anti-vegf
|
|
BRPI0808418A2
(pt)
|
2007-03-02 |
2014-07-22 |
Genentech, Inc |
Predição de resposta a um inibidor de her
|
|
WO2008119567A2
(en)
†
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific cd3-epsilon binding domain
|
|
AU2008234019B2
(en)
*
|
2007-04-03 |
2014-05-29 |
Amgen Research (Munich) Gmbh |
Cross-species-specific bispecific binders
|
|
US20090304590A1
(en)
*
|
2007-05-29 |
2009-12-10 |
Wyeth |
Therapeutic compositions and methods
|
|
US20090258005A1
(en)
*
|
2007-05-29 |
2009-10-15 |
Trubion Pharmaceuticals Inc. |
Therapeutic compositions and methods
|
|
ES2583377T3
(es)
|
2007-06-08 |
2016-09-20 |
Genentech, Inc. |
Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
|
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
CA2779436A1
(en)
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
|
NZ594665A
(en)
|
2009-03-20 |
2013-08-30 |
Genentech Inc |
Bispecific anti-her antibodies
|
|
SG176073A1
(en)
|
2009-05-29 |
2011-12-29 |
Hoffmann La Roche |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
|
WO2011084496A1
(en)
*
|
2009-12-16 |
2011-07-14 |
Abbott Biotherapeutics Corp. |
Anti-her2 antibodies and their uses
|
|
MX2012008958A
(es)
|
2010-02-18 |
2012-08-23 |
Genentech Inc |
Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
|
|
CN102167742B
(zh)
|
2010-02-25 |
2014-05-14 |
上海百迈博制药有限公司 |
一种全人源抗her2单克隆抗体、其制备方法及用途
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
|
CA2818635C
(en)
|
2010-12-06 |
2021-06-15 |
National Reseach Council Of Canada |
Antibodies selective for cells presenting erbb2 at high density
|
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
|
MY194408A
(en)
|
2011-10-14 |
2022-11-30 |
Genentech Inc |
Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab
|
|
US9327023B2
(en)
|
2011-10-25 |
2016-05-03 |
The Regents Of The University Of Michigan |
HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
RU2019103083A
(ru)
|
2011-11-30 |
2019-03-22 |
Дженентек, Инк. |
МУТАЦИИ ErbB3 ПРИ РАКЕ
|
|
EP2788500A1
(en)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
|
HUE035207T2
(en)
*
|
2012-01-13 |
2018-05-02 |
Univ Wuerzburg J Maximilians |
Dual antigen-induced bipartite functional complementation
|
|
WO2013148315A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
|
KR101505157B1
(ko)
|
2012-05-08 |
2015-03-24 |
주식회사 종근당 |
항―ＥｒｂＢ２ 항체 변이체
|
|
WO2014052713A2
(en)
|
2012-09-27 |
2014-04-03 |
Massachusetts Institute Of Technology |
Her2-and vegf-a-binding proteins with enhanced stability
|
|
KR101645905B1
(ko)
|
2012-10-12 |
2016-08-04 |
스피로즌 살 |
피롤로벤조디아제핀 및 그의 컨주게이트
|
|
US9492563B2
(en)
|
2012-10-30 |
2016-11-15 |
Esperance Pharmaceuticals, Inc. |
Antibody/drug conjugates and methods of use
|
|
JP6998646B2
(ja)
|
2012-11-30 |
2022-02-04 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
|
|
EP2968585B1
(en)
|
2013-03-13 |
2018-07-18 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
MX2015014181A
(es)
|
2013-04-09 |
2016-05-24 |
Boston Biomedical Inc |
2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
|
|
TWI554284B
(zh)
|
2013-04-16 |
2016-10-21 |
建南德克公司 |
帕妥珠單抗（ｐｅｒｔｕｚｕｍａｂ）變體及其評估
|
|
JP2016520586A
(ja)
*
|
2013-05-08 |
2016-07-14 |
ザイムワークス，インコーポレイテッド |
二重特異性ｈｅｒ２およびｈｅｒ３抗原結合性構築物
|
|
KR102225489B1
(ko)
|
2013-12-17 |
2021-03-10 |
제넨테크, 인크. |
항-cd3 항체 및 이의 사용 방법
|
|
CA2925677A1
(en)
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Bispecific her2 antibodies and methods of use
|
|
WO2015138435A1
(en)
|
2014-03-11 |
2015-09-17 |
Molecular Templates, Inc. |
Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
|
|
EP3872090A1
(en)
|
2014-03-11 |
2021-09-01 |
Molecular Templates, Inc. |
Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions
|
|
ES2819863T3
(es)
*
|
2014-04-11 |
2021-04-19 |
Medimmune Llc |
Anticuerpos contra HER2 biespecíficos
|
|
RU2020120593A
(ru)
|
2014-04-25 |
2020-09-01 |
Дженентек, Инк. |
Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
|
|
WO2016037644A1
(en)
|
2014-09-10 |
2016-03-17 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
KR101515535B1
(ko)
|
2015-01-28 |
2015-05-06 |
주식회사 종근당 |
항―ＥｒｂＢ２ 항체 변이체
|
|
CN105985435B
(zh)
|
2015-01-30 |
2019-10-15 |
嘉和生物药业有限公司 |
全人源her2抗体的突变抗体及其编码基因和应用
|
|
JP6771492B2
(ja)
|
2015-05-30 |
2020-10-21 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
脱免疫化された志賀毒素ａサブユニット足場及びそれを含む細胞標的化分子
|
|
WO2016196373A2
(en)
|
2015-05-30 |
2016-12-08 |
Genentech, Inc. |
Methods of treating her2-positive metastatic breast cancer
|
|
JP2018521979A
(ja)
|
2015-06-03 |
2018-08-09 |
ボストン バイオメディカル， インコーポレイテッド |
癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物
|
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
ES3043088T3
(en)
*
|
2015-06-17 |
2025-11-24 |
Hoffmann La Roche |
Anti-her2 antibodies and methods of use
|
|
MX2018001208A
(es)
|
2015-07-26 |
2018-03-26 |
Molecular Templates Inc |
Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
|
|
CN108430515B
(zh)
|
2015-10-29 |
2021-11-12 |
诺华股份有限公司 |
包含toll-样受体激动剂的抗体缀合物
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
|
US20190151346A1
(en)
|
2016-05-10 |
2019-05-23 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
|
JP2019534882A
(ja)
|
2016-10-11 |
2019-12-05 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
免疫介在性療法薬を有する抗体−薬物コンジュゲート
|
|
WO2018085513A1
(en)
|
2016-11-04 |
2018-05-11 |
Genentech, Inc. |
Treatment of her2-positive breast cancer
|
|
US11466094B2
(en)
|
2016-11-15 |
2022-10-11 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
|
JP7106563B2
(ja)
|
2016-11-29 |
2022-07-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
ナフトフラン誘導体、その調製、および使用方法
|
|
JP6914336B2
(ja)
|
2016-12-28 |
2021-08-04 |
ジェネンテック， インコーポレイテッド |
進行したｈｅｒ２発現がんの治療
|
|
CN117752782A
(zh)
|
2017-01-17 |
2024-03-26 |
豪夫迈·罗氏有限公司 |
皮下her2抗体配制剂
|
|
KR102590672B1
(ko)
|
2017-01-25 |
2023-10-18 |
몰레큘러 템플레이츠, 인코퍼레이션. |
탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
|
CN116531511A
(zh)
|
2017-03-02 |
2023-08-04 |
豪夫迈·罗氏有限公司 |
Her2阳性乳腺癌的辅助治疗
|
|
CN110382696B
(zh)
*
|
2017-03-07 |
2024-04-19 |
豪夫迈·罗氏有限公司 |
发现替代性抗原特异性抗体变体的方法
|
|
CN110536969A
(zh)
|
2017-04-24 |
2019-12-03 |
豪夫迈·罗氏有限公司 |
跨膜或近膜域中的erbb2/her2突变
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
US10646464B2
(en)
|
2017-05-17 |
2020-05-12 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
NZ762376A
(en)
|
2017-09-19 |
2022-08-26 |
Scherrer Inst Paul |
Transglutaminase conjugation method and linker
|
|
CN118772287A
(zh)
|
2018-02-08 |
2024-10-15 |
豪夫迈·罗氏有限公司 |
双特异性抗原结合分子和使用方法
|
|
MX2019009726A
(es)
|
2018-04-17 |
2020-02-05 |
Molecular Templates Inc |
Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.
|
|
JP2021524449A
(ja)
|
2018-05-23 |
2021-09-13 |
アーデーセー セラピューティクス ソシエテ アノニム |
分子アジュバント
|
|
US12460000B2
(en)
|
2018-09-07 |
2025-11-04 |
Itabmed (Hk) Limited |
Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
|
|
IL281344B2
(en)
|
2018-09-10 |
2025-09-01 |
Mirati Therapeutics Inc |
Combination of adagrasib and cetuximab for cancer treatment
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
CN113631580B
(zh)
*
|
2019-02-03 |
2024-07-02 |
上海宝济药业股份有限公司 |
抗her2的双特异性抗体及其应用
|
|
PE20221511A1
(es)
|
2019-12-13 |
2022-10-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y metodos de uso
|
|
WO2021151020A1
(en)
*
|
2020-01-23 |
2021-07-29 |
Bioatla, Inc. |
Conditionally active anti-her2 antibodies, antibody fragments their immunoconjugates and uses thereof
|
|
US20230072955A1
(en)
*
|
2020-01-23 |
2023-03-09 |
Exuma Biotech Corp |
Chimeric antigen receptors to her2 and methods of use thereof
|
|
KR20230006823A
(ko)
*
|
2020-04-30 |
2023-01-11 |
치아타이 티안큉 파마수티컬 그룹 주식회사 |
Her2를 표적화하는 항원 결합 구조체 및 이의 용도
|
|
KR20250151568A
(ko)
|
2020-06-29 |
2025-10-21 |
제넨테크, 인크. |
퍼투주맙 + 트라스투주맙 고정 용량 조합
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
PE20231512A1
(es)
|
2020-10-25 |
2023-09-26 |
Araris Biotech Ag |
Medios y metodos para producir conjugados de ligador-anticuerpo
|
|
IL303350A
(en)
|
2020-12-04 |
2023-08-01 |
Macrogenics Inc |
Pharmaceutical compositions of a her2/neu antibody and use of the same
|
|
WO2022159984A1
(en)
*
|
2021-01-22 |
2022-07-28 |
Bionecure Therapeutics, Inc. |
Anti-her-2/trop-2 constructs and uses thereof
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
WO2022241235A1
(en)
|
2021-05-14 |
2022-11-17 |
Genentech, Inc. |
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
WO2022078524A2
(en)
|
2021-11-03 |
2022-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
EP4551600A1
(en)
|
2022-07-04 |
2025-05-14 |
Vib Vzw |
Blood-cerebrospinal fluid barrier crossing antibodies
|
|
WO2024030341A1
(en)
|
2022-07-30 |
2024-02-08 |
Pinetree Therapeutics, Inc. |
Compositions for targeted lysosomal degradaton and methods of use thereof
|
|
WO2024061224A1
(zh)
*
|
2022-09-20 |
2024-03-28 |
普米斯生物技术(珠海)有限公司 |
抗her2抗体及其用途
|
|
TW202434307A
(zh)
|
2023-01-18 |
2024-09-01 |
大陸商泰勵生物科技（上海）有限公司 |
抗體偶聯藥物及其用途
|
|
CN121358771A
(zh)
|
2023-04-03 |
2026-01-16 |
非营利性组织佛兰芒综合大学生物技术研究所 |
血-脑屏障穿越抗体
|
|
WO2026032417A1
(zh)
*
|
2024-08-08 |
2026-02-12 |
石药集团巨石生物制药有限公司 |
Gspt1降解剂和含有gspt1降解剂的抗体偶联物及其用途
|